The success of targeted cancer therapy has transformed survival rates for patients over the last two decades, enhancing drug efficacy and reducing side effects, in comparison with standard chemotherapies.
This infographic charts the rise of small molecule therapies targeting druggable mutations such as BCR-ABL, ALK and KRAS - from first to third generation kinase inhibitors, to innovations in structure-based design of allosteric modulators and the promise of versatile and potent modalities such as PROTACs.
Comments